VOLTAREN ARTHRITIS PAIN Drug Patent Profile

Which patents cover Voltaren Arthritis Pain, and what generic alternatives are available?

Voltaren Arthritis Pain is a drug marketed by Haleon Us Holdings and is included in one NDA.

The generic ingredient in VOLTAREN ARTHRITIS PAIN is diclofenac sodium. There is one drug master file entry for this compound. One hundred and twenty-four suppliers are listed for this compound. Additional details are available on the diclofenac sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Voltaren Arthritis Pain

A generic version of VOLTAREN ARTHRITIS PAIN was approved as diclofenac sodium by ACTAVIS ELIZABETH on March 26^th, 1996.

Summary for VOLTAREN ARTHRITIS PAIN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	121
Clinical Trials:	1
Patent Applications:	6,910
What excipients (inactive ingredients) are in VOLTAREN ARTHRITIS PAIN?	VOLTAREN ARTHRITIS PAIN excipients list
DailyMed Link:	VOLTAREN ARTHRITIS PAIN at DailyMed

Recent Clinical Trials for VOLTAREN ARTHRITIS PAIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Zambon SpA	Phase 1
Cross Research S.A.	Phase 1

See all VOLTAREN ARTHRITIS PAIN clinical trials

Pharmacology for VOLTAREN ARTHRITIS PAIN

Drug Class	Nonsteroidal Anti-inflammatory Drug
Mechanism of Action	Cyclooxygenase Inhibitors
Physiological Effect	Decreased Prostaglandin Production

US Patents and Regulatory Information for VOLTAREN ARTHRITIS PAIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Haleon Us Holdings	VOLTAREN ARTHRITIS PAIN	diclofenac sodium	GEL;TOPICAL	022122-001	Oct 17, 2007		OTC	Yes	Yes

# Voltaren Arthritis Pain Market Dynamics, Financial Trajectory, Patents, and Competitive Outlook

Last updated: August 24, 2026

Voltaren Arthritis Pain is Haleon’s U.S. over-the-counter diclofenac sodium 1% topical gel for temporary relief of arthritis pain. Its commercial position rests on the 2020 FDA switch from prescription to OTC status, strong physician familiarity with diclofenac, and a differentiated topical NSAID proposition. The product operates in a competitive market with generic diclofenac gel, other topical analgesics, oral NSAIDs, and private-label products.

Haleon does not report Voltaren Arthritis Pain revenue as a standalone line item. Financial analysis therefore relies on Haleon’s broader Pain Relief category, brand disclosures, retail-market data, and the product’s distribution and regulatory milestones. The principal long-term risks are generic price competition, consumer substitution, retailer private labels, limited differentiation of a mature active ingredient, and the absence of meaningful product-specific regulatory exclusivity.

What is Voltaren Arthritis Pain and how does it work?

Voltaren Arthritis Pain contains diclofenac sodium 1% in a topical gel formulation. It is labeled for temporary relief of arthritis pain in joints suitable for topical treatment, including the hands, wrists, elbows, feet, ankles, and knees.

Diclofenac is a nonsteroidal anti-inflammatory drug, or NSAID. The topical route is intended to deliver the active ingredient at the site of pain while producing lower systemic exposure than oral diclofenac. The product’s consumer value proposition is based on localized treatment and avoidance of routine oral dosing.

Product attribute	Voltaren Arthritis Pain
Active ingredient	Diclofenac sodium
Strength	1%
Dosage form	Topical gel
U.S. regulatory status	OTC
Manufacturer and marketer	Haleon
Initial U.S. prescription product	Voltaren Gel
OTC launch	2020
Primary use	Temporary relief of arthritis pain
Core competitors	Generic diclofenac gel, Salonpas, Aspercreme, Bengay, Biofreeze, oral NSAIDs

The OTC version is distinct from prescription diclofenac products such as Pennsaid and Flector, which use different formulations, concentrations, indications, or delivery systems.

When did Voltaren Arthritis Pain become available over the counter?

The FDA approved the switch of Voltaren Arthritis Pain from prescription to OTC status in February 2020. Haleon, then operating within GSK Consumer Healthcare, launched the U.S. OTC product during 2020.

The switch expanded the addressable market in three ways:

1. Consumers could purchase the product without a physician visit.
2. The brand moved from a prescription channel into mass retail, pharmacy, grocery, and e-commerce.
3. Haleon could advertise directly to consumers seeking arthritis pain relief.

The OTC transition also changed the competitive basis of the product. Prescription Voltaren Gel competed primarily on clinical utility and physician prescribing. Voltaren Arthritis Pain competes on brand recognition, shelf placement, consumer education, promotional spending, price, and retailer availability.

The OTC approval did not create a new long-term market exclusivity period comparable to a new chemical entity. The active ingredient is established, and competing diclofenac topical products can enter through abbreviated or other applicable FDA pathways.

What is the financial trajectory of Voltaren Arthritis Pain?

Haleon does not disclose standalone revenue, operating profit, gross margin, or geographic sales for Voltaren Arthritis Pain. The brand is included within Haleon’s broader Pain Relief reporting structure.

Haleon’s financial disclosures identify Pain Relief as one of its largest consumer-health categories. Voltaren is a global brand within that category, alongside products such as Panadol and Advil in relevant markets. The company has reported category-level performance and brand-level growth commentary, but those disclosures do not isolate U.S. Voltaren Arthritis Pain sales.

Revenue trajectory by commercial phase

Period	Commercial development	Financial implication
Before 2020	Prescription Voltaren Gel	Narrower access and lower consumer reach
2020	U.S. OTC switch and launch	Distribution expansion and consumer advertising opportunity
2021-2022	Retail penetration and brand-building	Higher trial potential, with launch and promotional costs
2022	Transfer into Haleon following separation from GSK	Independent consumer-health reporting structure
2023-2024	Mature OTC brand management	Growth increasingly dependent on category expansion, pricing, distribution, and repeat purchase
Longer term	Generic and private-label pressure	Potential volume erosion and lower realized price

The most likely financial pattern is a sharp increase in U.S. consumer reach after the OTC switch, followed by normalization as awareness matured. The product’s revenue trajectory is unlikely to resemble a protected specialty pharmaceutical with sustained price expansion. It is a mature branded OTC asset whose value depends on repeat use, household penetration, brand trust, and retail execution.

Haleon’s reported group performance is more useful for assessing corporate exposure than for estimating product-specific earnings. Voltaren contributes to Pain Relief revenue, but public filings do not provide a reliable standalone valuation or revenue forecast for the brand. [1][2]

How large is the market for topical arthritis pain products?

The addressable market is supported by the aging population, osteoarthritis prevalence, consumer preference for self-care, and demand for treatments perceived to have lower systemic exposure than oral NSAIDs.

Topical arthritis pain products occupy a position between:

• Oral analgesics and NSAIDs
• Prescription topical formulations
• Non-drug products such as braces and heat wraps
• Counterirritants containing menthol, methyl salicylate, or capsaicin
• Private-label diclofenac products

Voltaren’s strongest category advantage is that diclofenac is a clinically established NSAID rather than a counterirritant. Its main commercial disadvantage is that the active ingredient is not proprietary, and consumers can often purchase lower-priced generic alternatives.

Retail execution is material. The product must secure prominent placement in pain-relief aisles, pharmacy sections, retailer websites, and search advertising. Price promotions can stimulate trial but may reduce net revenue per unit. E-commerce also increases price transparency and makes generic substitution easier.

Which companies challenge Voltaren Arthritis Pain?

The competitive field includes branded topical analgesics, generic diclofenac products, private-label retailers, and oral pain-relief products.

Competitor group	Representative products or companies	Competitive effect
Generic diclofenac gel	Authorized and independent generic manufacturers	Direct substitution on active ingredient and strength
Topical counterirritants	Salonpas, Aspercreme, Bengay, Biofreeze	Compete for the same pain-relief budget
Prescription topicals	Pennsaid, Flector, other diclofenac formulations	Compete in clinician-directed treatment
Oral NSAIDs	Advil, Aleve, Motrin and generics	Compete on broader pain relief and convenience
Retail private labels	Pharmacy, mass-retail, and e-commerce store brands	Apply price pressure and increase switching
Non-drug products	Heat patches, braces, wraps	Address the same consumer need through alternative mechanisms

Voltaren has a stronger brand position than an unbranded generic, but that advantage carries marketing costs. Generic diclofenac can compete with materially lower prices because it does not need to recover comparable consumer advertising or brand-building expenditure.

What patents protect Voltaren Arthritis Pain?

The principal U.S. intellectual-property position originated with topical diclofenac gel technology and the prescription Voltaren Gel product. Key patent protection associated with diclofenac topical gel included U.S. Patent No. 6,548,491, which covered topical gel compositions containing diclofenac and related formulation concepts. The patent expired in the United States in the early 2020s based on its original term and applicable adjustments.

The commercial implications are clear:

• Core active-ingredient protection is long expired.
• The OTC product does not have new chemical entity exclusivity.
• Formulation or manufacturing patents, if enforceable and relevant, would have narrower scope than active-ingredient protection.
• Brand, packaging, consumer trust, retail access, and advertising are now more important than basic compound exclusivity.

Are Voltaren Arthritis Pain patents listed in the Orange Book?

The Orange Book primarily identifies patents and exclusivity associated with approved prescription drug products. Voltaren Arthritis Pain is an OTC product, while the original Voltaren Gel was approved as a prescription drug.

The OTC switch does not automatically create a new Orange Book patent estate. Any analysis of listed patents must distinguish between:

1. The prescription Voltaren Gel NDA and its historical listings.
2. The OTC labeling and marketing authorization.
3. Generic prescription diclofenac products.
4. Separate patents covering delivery systems, formulations, or manufacturing processes.

A historical Orange Book listing for the prescription product would not by itself prevent OTC or generic topical competition after expiration. [3]

When does Voltaren Arthritis Pain lose exclusivity?

Voltaren Arthritis Pain has no meaningful remaining exclusivity comparable to a newly approved prescription product. The relevant core patent protection has expired or is no longer a practical barrier to generic topical diclofenac competition.

The product’s effective commercial protection is therefore non-patent exclusivity:

Protection type	Current commercial relevance
New chemical entity exclusivity	None
Prescription patent protection	Historical and largely expired
OTC regulatory exclusivity	Limited relative to new drug exclusivity
Trademark protection	Active and commercially important
Trade dress and packaging	Potentially enforceable, but does not block generic entry
Consumer advertising	Supports brand preference, not market exclusivity
Distribution relationships	Important for shelf access and conversion

Trademark protection can prevent confusingly similar branding, but it cannot prevent competitors from selling diclofenac gel under generic names or private labels.

What generic entry risks exist for Voltaren Arthritis Pain?

Generic entry risk is high because the product uses a mature active ingredient in a simple topical dosage form. The main entry barriers are regulatory equivalence, formulation performance, manufacturing quality, and commercial distribution rather than compound discovery.

Generic manufacturers can challenge the brand through:

• Lower retail pricing
• Pharmacy and retailer substitution
• Private-label contracts
• Online search placement
• Smaller promotional budgets
• Large-scale manufacturing economics

Topical products can present more complex equivalence questions than conventional immediate-release tablets because formulation characteristics, drug release, skin permeation, and manufacturing controls can affect performance. That complexity may delay or narrow generic competition, but it does not restore the type of exclusivity associated with an unexpired composition-of-matter patent.

Are Paragraph IV challenges relevant to Voltaren Arthritis Pain?

Paragraph IV litigation is most relevant to an abbreviated new drug application directed at an approved prescription product with Orange Book-listed patents. The OTC Voltaren Arthritis Pain product itself is not typically the main target of a conventional Paragraph IV strategy because OTC products do not use the same Orange Book framework as prescription NDAs.

Potential litigation could still arise from:

• ANDA filings for prescription diclofenac gel
• Patent claims covering formulation or manufacturing methods
• Trademark and trade-dress disputes
• False advertising or comparative marketing
• Product-liability claims
• Regulatory disputes concerning OTC labeling or monograph compliance

The absence of a major current Paragraph IV case would not remove generic risk. It would indicate that competition is more likely to arise through ordinary generic approvals, retailer substitution, or OTC alternatives.

What manufacturing and formulation barriers protect Voltaren?

The formulation is commercially important even though it is not strongly protected by the active ingredient. A topical gel manufacturer must control:

• Diclofenac uniformity
• Viscosity and spreadability
• Drug release
• Skin permeation
• Stability
• Preservative performance
• Packaging compatibility
• Container dosing and consumer use

These requirements can create practical development and quality barriers. They do not necessarily create durable legal exclusivity. A competitor that successfully demonstrates an equivalent product can compete without duplicating Haleon’s exact excipient profile or manufacturing process.

Haleon’s principal defensible assets are the Voltaren trademark, established consumer awareness, product claims supported by the approved label, retail relationships, and manufacturing scale.

What regulatory issues affect Voltaren Arthritis Pain?

FDA regulation imposes limits on labeling, claims, warnings, dosing instructions, age restrictions, and advertising. The product cannot be marketed as providing unapproved disease modification or as eliminating the risks associated with systemic NSAIDs.

Commercial growth must remain consistent with the OTC label. Relevant risk areas include:

• Consumer misunderstanding of topical versus systemic NSAID exposure
• Use on unapproved body sites
• Excessive dosing or duration
• Concomitant use with other NSAIDs
• Cardiovascular, gastrointestinal, renal, and allergic warnings
• Advertising claims that exceed the approved indication

The 2020 switch reduced access friction, but it also placed greater responsibility on consumer-facing education and compliant advertising. [4]

How does Voltaren compare with prescription diclofenac products?

Factor	Voltaren Arthritis Pain	Prescription diclofenac products
Access	OTC	Prescription
Consumer decision	Self-directed	Clinician-directed
Commercial channel	Retail and e-commerce	Pharmacy prescription channel
Main differentiation	Brand, convenience, OTC access	Formulation, indication, and clinical management
Price pressure	High from generics and private labels	High from generic substitution
Patent relevance	Limited for OTC product	More relevant to listed prescription products
Growth driver	Consumer penetration and repeat use	Diagnosis, prescribing, reimbursement, and adherence

Voltaren Arthritis Pain has broader consumer access but less regulatory and patent protection. Prescription products retain greater potential for formulation-specific differentiation, while facing payer and generic substitution constraints.

What is the investment outlook for Voltaren Arthritis Pain?

Voltaren is strategically valuable as a branded OTC asset, but its financial profile is defensive rather than high-growth. The product can support Haleon through:

• Strong brand recognition
• High category relevance
• OTC convenience
• Global brand transferability
• Premium pricing relative to unbranded alternatives
• Cross-channel retail distribution

The main risks are:

• Standalone sales opacity
• Generic diclofenac substitution
• Private-label competition
• Promotional price erosion
• Mature-category growth rates
• Consumer switching to cheaper topical products
• Limited patent protection
• Advertising and regulatory compliance costs

The most credible base case is stable to moderate nominal growth driven by pricing, distribution, and category expansion, with volume growth constrained by generic and private-label competition. A stronger outcome would require sustained brand investment, successful international execution, and continued consumer preference for topical NSAIDs over oral products.

Key takeaways

• Voltaren Arthritis Pain is Haleon’s OTC diclofenac sodium 1% topical gel for arthritis pain.
• The U.S. OTC switch occurred in 2020 and materially expanded consumer access.
• Haleon does not disclose standalone Voltaren Arthritis Pain revenue.
• The brand is reported within Haleon’s broader Pain Relief portfolio.
• Core diclofenac and topical-gel patent protection is historical and does not provide a durable current barrier to generic entry.
• The principal defenses are trademark, brand recognition, retail distribution, advertising, and manufacturing scale.
• Generic diclofenac gel and private-label products present the highest direct commercial risk.
• Paragraph IV litigation is more relevant to prescription diclofenac products than to the OTC brand.
• Voltaren’s financial trajectory is likely to be mature-brand growth rather than exclusivity-driven pharmaceutical growth.
• Haleon’s value capture depends on premium pricing and repeat consumer use despite equivalent lower-cost alternatives.

FAQs about Voltaren Arthritis Pain

Is Voltaren Arthritis Pain the same as prescription Voltaren Gel?

It uses the same general active ingredient and 1% topical gel strength in the U.S. OTC product, but the regulatory status, labeling, consumer access, and marketing framework differ.

Can pharmacies substitute generic diclofenac for Voltaren Arthritis Pain?

Retailers may offer generic diclofenac gel as an alternative, but substitution practices depend on product authorization, pharmacy rules, retailer policy, and consumer selection.

Does Voltaren Arthritis Pain have a patent that blocks generic gel?

No current core patent is understood to provide durable exclusivity over diclofenac sodium 1% topical gel. Formulation or process patents could have narrower relevance.

Who owns the Voltaren brand?

Haleon owns and markets the brand following the separation of GSK’s consumer-health business into Haleon in 2022.

Is Voltaren Arthritis Pain approved for all types of pain?

No. Its OTC labeling is directed to temporary relief of arthritis pain in specified joints. Marketing claims outside the approved labeling can create regulatory risk.

References

1. Haleon plc. (2024). Annual report and financial statements 2023. Haleon.
2. Haleon plc. (2025). Annual report and financial statements 2024. Haleon.
3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
4. U.S. Food and Drug Administration. (2020, February 14). FDA approves first over-the-counter topical gel for temporary relief of arthritis pain. FDA.
5. U.S. Patent No. 6,548,491. (2003). Topical compositions containing diclofenac. United States Patent and Trademark Office.